<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30187035</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>22</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>22</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">2047-4849</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>6</Volume>                    <Issue>10</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>25</Day>                    </PubDate>                </JournalIssue>                <Title>Biomaterials science</Title>                <ISOAbbreviation>Biomater Sci</ISOAbbreviation>            </Journal>            <ArticleTitle>Primary tumor and pre-metastatic niches co-targeting &quot;peptides-lego&quot; hybrid hydroxyapatite nanoparticles for metastatic breast cancer treatment.</ArticleTitle>            <Pagination>                <MedlinePgn>2591-2604</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1039/c8bm00706c</ELocationID>            <Abstract>                <AbstractText>Both tumor metastasis resisting therapy (TMRT) and tumor metastasis targeting therapy (TMTT) attempt to improve tumor metastasis treatment, but they are limited by dynamic metastatic escape or insufficient micrometastases drug accumulation, respectively. Doxorubicin (DOX)-loaded functional peptide combination (PMC)-modified hydroxyapatite (HP) multi-mode nanoparticles (DPH) were developed to realize tumor metastasis amphibious therapy by balancing TMRT and TMTT. An in vivo imaging study showed that DPH had efficient drug delivery ability targeting to primary tumor and micrometastasis. Besides, it was found that cathepsin B-triggered intracellular mitochondria and nuclei dual-targeted treatment could enhance the antitumor effect of DOX by a synergistic effect. DPH treatment finally achieved both primary tumor and micrometastases reduction in 4T1 aggressive lung metastasis models. The tumor metastasis inhibition of DPH was attributed to blocking the mitochondrial escape signaling pathways. The results also showed the enhanced anticancer benefits of DPH, which could orchestrate TMRT and TMTT in contrast to a mixture of DOX and PH (PMC-modified HP nanoparticles). Overall, we generated multi-mode nanoparticles that could flexibly realize amphibious therapy for metastatic cancer while reducing systemic drug exposure and off-target toxicities.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Xiong</LastName>                    <ForeName>Hui</ForeName>                    <Initials>H</Initials>                    <Suffix/>                    <AffiliationInfo>                        <Affiliation>State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, Department of Pharmaceutics, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China. yaojing@cpu.edu.cn.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Du</LastName>                    <ForeName>Shi</ForeName>                    <Initials>S</Initials>                    <Suffix/>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Ping</ForeName>                    <Initials>P</Initials>                    <Suffix/>                </Author>                <Author ValidYN="Y">                    <LastName>Jiang</LastName>                    <ForeName>Zhijie</ForeName>                    <Initials>Z</Initials>                    <Suffix/>                </Author>                <Author ValidYN="Y">                    <LastName>Zhou</LastName>                    <ForeName>Jianping</ForeName>                    <Initials>J</Initials>                    <Suffix/>                </Author>                <Author ValidYN="Y">                    <LastName>Yao</LastName>                    <ForeName>Jing</ForeName>                    <Initials>J</Initials>                    <Suffix/>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Biomater Sci</MedlineTA>            <NlmUniqueID>101593571</NlmUniqueID>            <ISSNLinking>2047-4830</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000903">Antibiotics, Antineoplastic</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D005353">Fibronectins</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C535058">KLA peptide</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D009842">Oligopeptides</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D010455">Peptides</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C542438">cysteinyl-arginyl-glutamyl-lysyl-alanyl</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>80168379AG</RegistryNumber>                <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>91D9GV0Z28</RegistryNumber>                <NameOfSubstance UI="D017886">Durapatite</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000903" MajorTopicYN="N">Antibiotics, Antineoplastic</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017886" MajorTopicYN="N">Durapatite</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005353" MajorTopicYN="N">Fibronectins</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008325" MajorTopicYN="N">Mammary Neoplasms, Experimental</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009206" MajorTopicYN="N">Myocardium</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009842" MajorTopicYN="N">Oligopeptides</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013154" MajorTopicYN="N">Spleen</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>7</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>7</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30187035</ArticleId>            <ArticleId IdType="doi">10.1039/c8bm00706c</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>